TB Alliance

New pathways for childhood TB treatment: Lessons from the STEP-TB project

TB Alliance and Unitaid released a report, New pathways for childhood TB treatment: Lessons from the STEP-TB project, documenting how the STEP-TB project has reshaped the market for pediatric TB drugs by reducing barriers to entry, engaging in innovative industry collaboration to launch optimized products for children, and mobilizing strong demand. Since launching in 2015, these new medicines have begun to reach children around the world, setting a precedent for future action in the fight to end TB.

Read More →

TB Alliance moves two novel TB drugs into human trials

GUADALAJARA (10 October, 2017) — TBA-7371 and sutezolid entered phase 1 clinical trials, TB Alliance announced today. Both compounds have proceeded through early preclinical development and were granted “Investigative New Drug” status by the U.S. Food and Drug Administration. The phase 1 clinical trials are presently ongoing. 

Read More →

EU leaders seek new tools against drug-resistant TB

EU leaders urge funding for new treatment and prevention tools against drug-resistant TB.

Read More →

TB Alliance sublicenses promising TB drug from the Medicines Patent Pool

Agreement announced on World Tuberculosis Day revitalizes efforts to develop sutezolid as effective response to infectious disease killer.

Read More →

World TB Day event: Innovating to End TB

USAID and TB Alliance will host an event, Innovating to End TB on 14 March 2017, 12:00 PM – 6:30 PM EDT in Washington, D.C., United States.

Read More →

Clinical trial of BPaMZ regimen will replace Phase 3 STAND trial

NEW YORK (21 December, 2016)—TB Alliance announced, based on positive results from the Phase 2b NC-005 trial, that it will now plan a Phase 3 study to test the BPaMZ (bedaquiline + pretomanid + moxifloxacin + pyrazinamide) regimen. In light of these results, where the BPaMZ regimen appears to be much more promising compared to the PaMZ (pretomanid + moxifloxacin + pyrazinamide) regimen, the STAND trial testing the PaMZ regimen will not be reopened to new patients. 

Read More →

German government announces support for new TB treatments

The government of Germany has announced its support for the development of new treatments to combat tuberculosis (TB). Germany’s Federal Ministry of Education and Research (BMBF) has committed EUR 10 million over five years to TB Alliance, facilitated by the KfW development bank. This grant is part of a slate of support intended to spur product development to fight neglected diseases.

Read More →

TB Alliance partners with PepsiCo to advance the fight for improved medicines for children

October 27, 2016 (LIVERPOOL, ENGLAND) – TB Alliance, a non-profit organization dedicated to developing better and faster cures for tuberculosis (TB), today announced a unique collaboration with food and beverage company PepsiCo designed to improve the treatment for children with TB.  Many of today’s TB treatments are very bitter or unpleasant in taste, which when compounded with the long duration of treatment for TB, can lead to low tolerance and poor compliance – especially among children. 

Read More →

Kenya becomes first country to introduce new child-friendly TB medicines

New products expected to improve treatment and child survival from TB; Starting October 1 all children in Kenya initiated on TB treatment will be given the improved formulation.

Read More →

TB Alliance Stakeholders Association: Call for community representative

The Global Alliance for TB Drug Development (TB Alliance) is seeking applications for the community representative to its Stakeholders Association.

Read More →

Page 1 of 6 · Total posts: 10

1 2 Last→